Mitsubishi Tanabe and Dewpoint Therapeutics Collaborate on $480M ALS Treatment Development

Partnership:
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic research partnership to develop a TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS)13.

Deal Value:
The collaboration is valued at up to $480 million, with Dewpoint receiving an upfront payment and being eligible for milestone payments based on specified research and development objectives13.

Licensing Option:
Upon achieving these milestones, MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization13.

Royalties:
Dewpoint will earn tiered royalties on the net sales of the treatment13.

TDP-43 Significance:
TDP-43 is a protein present in more than 97% of ALS patients and plays a significant role in neurodegenerative conditions13.

Condensate Biology:
Dewpoint’s expertise in condensate biology led to the discovery of a small molecule that counteracts the mislocalization of TDP-43, aiming to restore its normal function and improve ALS biomarkers13.

Collaboration Goals:
The partnership aims to address the critical unmet need in ALS treatment by leveraging MTPC’s expertise in ALS and Dewpoint’s pioneering condensate-targeted platform13.

Sources:

1. https://www.pharmaceutical-technology.com/news/dewpoint-mitsubishi-tanabe-als/

3. https://www.globenewswire.com/news-release/2024/12/04/2991446/0/en/Dewpoint-Therapeutics-and-Mitsubishi-Tanabe-Pharma-Corporation-Enter-Research-Collaboration-to-Advance-Small-Molecule-Condensate-Modulator-for-ALS.html